Prebiotic

Arrabina P for Satiety

Tampa, FL

N/A

Waitlist Available

Research Sponsored by Comet Bio Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Female participants must have a regular menstrual cycle, no longer menstruate due to medication or menopause, or have medically documented ovarian failure

Be between 18 and 65 years old

Must not have

History of heart/cardiovascular disease, renal disease, hepatic impairment, immune disorders, or cancer within 5 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 12

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to see if a prebiotic product called Arrabina P can help control appetite, improve gut health, and aid in weight management in healthy adults.

See full description

Who is the study for?

This trial is for healthy adults interested in managing their appetite and supporting gut health, potentially aiding weight management. Specific eligibility criteria are not provided, but typically participants should be free from significant health issues that could affect the study's outcome.Check my eligibility

What is being tested?

The study tests two different doses of Arrabina P Prebiotic (3.5 g and 5.0 g) against a placebo to see if they can help control hunger and support digestive wellness in healthy individuals.See study design

What are the potential side effects?

While specific side effects are not listed, prebiotics like Arrabina P may sometimes cause mild digestive discomfort such as bloating or gas, especially when first starting the supplement.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a woman with a regular menstrual cycle, in menopause, or have ovarian failure.

show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I haven't had heart, kidney, liver diseases, immune disorders, or cancer in the last 5 years.

show original

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 12

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 12

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Secondary study objectives

Subgroup only: To evaluate the effect of TP at two dose levels on postprandial glucose and insulin response, compared to placebo

To evaluate the effect of TP at two dose levels on appetite control, compared to placebo

To evaluate the effect of TP at two dose levels on blood lipid biomarkers, compared to placebo

+8 more

Other study objectives

Subgroup only: To evaluate the effect of TP at two dose levels on gut metabolomics in blood, compared to placebo in subgroup of participants

Subgroup only: To evaluate the effect of TP at two dose levels on postprandial appetite regulating hormone response, compared to placebo

Subgroup only: To evaluate the effect of TP at two dose levels on postprandial inflammatory response, compared to placebo in a subgroup of participants

+4 more